Drug Pricing Transparency and Accountability Act

Drug Pricing Transparency and Accountability Act

This bill establishes a two-year moratorium on allowing new, non-rural hospitals and associated child sites to participate in the 340B drug pricing program; during the moratorium, the Department of Health and Human Services must issue regulations with specified program eligibility standards. The bill also requires additional reporting relating to program participation, eligibility, and costs.

Bill 118 HR 198, also known as the Drug Pricing Transparency and Accountability Act, aims to address the issue of rising prescription drug prices in the United States. The bill was introduced in the House of Representatives and is currently under consideration by the Committee on Energy and Commerce.

The main provisions of the bill include requiring pharmaceutical companies to provide detailed information on the costs of producing and marketing their drugs, as well as the prices they charge for those drugs. This information would be made publicly available in order to increase transparency and hold drug companies accountable for their pricing practices.

Additionally, the bill seeks to establish a Drug Pricing Review Board, which would be responsible for reviewing and approving any price increases for prescription drugs. The board would have the authority to reject price increases that are deemed to be unjustified or excessive. Furthermore, the bill includes measures to increase competition in the pharmaceutical industry, such as allowing the importation of cheaper drugs from other countries and promoting the development of generic alternatives to brand-name drugs. Overall, the Drug Pricing Transparency and Accountability Act aims to address the issue of skyrocketing drug prices in the United States by increasing transparency, promoting competition, and holding pharmaceutical companies accountable for their pricing practices.